US Patent

US11890326 — Controlled-release PTH compound

Composition of Matter · Assigned to Ascendis Pharma Bone Diseases AS · Expires 2037-09-28 · 11y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a controlled-release compound made by reversibly conjugating parathyroid hormone (PTH(1-34)) to a branched polyethylene glycol.

USPTO Abstract

The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.

Drugs covered by this patent

Patent Metadata

Patent number
US11890326
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-09-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ascendis Pharma Bone Diseases AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.